Home / Pharmaceutical / Triple Negative Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey

Triple Negative Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey

Published: Jan 2011 | No Of Pages: 36 | Published By: Assessment Group

Product Synopsis

 
Primary research that presents a patient specific case scenario unfolding throughout the report, to 174 high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their open responses on specific clinical decisions. 
 
Patient progression reveals:
 
  • Decisions in treatment throughout patient stages
  • Factors influencing their decisions
  • Barriers to optimal care
  • Confidence in treatment.
 
Data has been synthesized to show the highest reported responses, “other” responses, and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Triple Negative Metastatic Breast Cancer. 
 
Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer. 
 
This report allows you to:
 
  • Understand what occurs with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing and improving your market strategies
  • Pinpoint needs of your target audience
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your product fits
  • Understand where your competitor’s product fits
  • Design messages to advance brand performance
 
Specific patient case scenario that unfolds throughout the report, presented to high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their clinical decisions. Out of 174 oncologists’ responses, those who use combination chemotherapy were most likely to use xx and xx. Oncologists who use a single agent were most likely to use x or x. Key factors in the choice of therapy include the following….
Executive Summary
 
Chapter 1: Introduction
Table 1. Treatment Options in Triple Negative Metastatic Breast Cancer
 
Chapter 2: Respondent Demographics
Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
 
Chapter 3: Treatment of a Patient with Triple Negative Metastatic Breast Cancer
Choice of chemotherapy regimen, triple negative metastatic breast cancer
Figure 3.1
Single chemotherapy choices, triple negative metastatic breast cancer
Figure 3.2
Combination chemotherapy choices, triple negative metastatic breast cancer
Figure 3.3
Factors influencing treatment of triple negative metastatic breast cancer
Figure 3.4
Confidence managing patient with triple negative metastatic breast cancer
Figure 3.5
Other agents appropriate to include in treatment of triple negative metastatic breast cancer
Figure 3.1
Treatment of progressive triple negative metastatic breast cancer
Figure 3.2
Single chemotherapy agent, progressive triple negative metastatic breast cancer
Figure 3.3
Combination chemotherapy, progressive triple negative metastatic breast cancer
Figure 3. 4
Barriers to optimal treatment of progressive triple negative metastatic breast cancer
Figure 3.5
Changing therapy to manage neuropathy
Figure 3.6
Recommended treatment of progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.7
Single agent chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.8
Combination chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.9
 
Chapter 4. Summary
Appendix A: Survey Instrument
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +